Cytoreductive surgery and modified heated intraoperative intraperitoneal chemotherapy (HIPEC) for advanced and recurrent ovarian cancer - 12-year single center experience

European Journal of Surgical Oncology

Volumn 35, Issue 11, 2009, Pages 1186-1191

  Pavlov, M J ^a   Kovacevic, P A ^a   Ceranic, M S ^a   Stamenkovic, A B ^a   Ivanovic, A M ^a   Kecmanovic, D M ^a  

^a CLINICAL CENTER OF SERBIA   (Serbia)

Author keywords

Cytoreduction; HIPEC; Primary ovarian cancer; Recurrent ovarian

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CHEMOSURGERY; CYTOREDUCTIVE SURGERY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HEATED INTRAOPERATIVE INTRAPERITONEAL CHEMOTHERAPY; HUMAN; MAJOR CLINICAL STUDY; MORBIDITY; MULTIPLE CYCLE TREATMENT; OPERATION DURATION; OVARY CANCER; POSTOPERATIVE CARE; PRIMARY TUMOR; PRIORITY JOURNAL; RECURRENT CANCER; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DOXORUBICIN; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 70349909874     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2009.03.004     Document Type: Article

References (24)

1. Parkin D.M., Pisani P., and Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 80 (1999) 827-841
2. Pisani P., Parkin D.M., Bray F., and Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 83 (1999) 18-29
3. FIGO annual report 2001. J Epidemiol Biostat 6 (2001) 1-184
4. Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L., and Montz F.J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20 (2002) 1248-1259
5. Look M., Chang D., and Sugarbaker P.H. Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Int J Gynecol Cancer 14 1 (2004 Jan-Feb) 35-41
6. Jacquet P., and Sugarbaker P.H. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 82 (1996) 359-374
7. In: Sugarbaker P.H. (Ed). Peritoneal carcinomatosis. Principles of management (1996), Kluver Academic, Boston
8. Sugarbaker P.H. Peritonectomy procedure. Ann Surg 221 (1995) 29-42
9. Meigs J.V. Ovarian tumors with endocrine significance. Ann Surg 102 5 (1935 Nov) 834-848
10. Meigs J.V. Tumors of the female pelvic organs (1934), Macmillan, New York, NY
11. Weisberger A.S., Levine B., and Storaasli J.P. Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. JAMA 159 (1955) 1704-1707
12. Griffiths C.T. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 42 (1975) 101-104
13. Hoskins W.J., Bundy B.N., Thigpen T.J., and Omura G.A. The influence of cytoreductive surgery on recurrence-free interval and survival in small volume stage 3 epithelial ovarian cancer: a Gynecologic Oncology Groups study. Gynecol Oncol 47 (1992) 59-66
14. Armstrong D.K., Bundy B., Wenzel L., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354 1 (2006) 34-43
15. Ryu K.S., Kim J.H., Ko H.S., et al. Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer. Gynecol Oncol 94 2 (2004 Aug) 325-332
16. Eisenkop S.M., Spirtos N.M., and Lin W.C.M. "Optimal" cytoreduction for advanced epithelial ovarian cancer: a commentary. Gynecol Oncol 103 (2006) 329-335
17. Vaart P.J.M., Vange N., Zoetmulder F.A.N., et al. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer 34 (1998) 148-154
18. Steller M.A., Egorin M.J., Trimble E.L., et al. A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer. Cancer Chemother Pharmacol 43 (1999) 106-114
19. Nicoletto M.O., Padrini R., Galeotti F., et al. Pharmacokinetics of hyperthermic intraperitoneal chemotherapy with mitoxantrone in ovarian cancer. Cancer Chemother Pharmacol 45 (2000) 457-462
20. Rufian S., Munoz-Casares F.C., Briceno J., et al. Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer. J Surg Oncol 94 4 (2006 Sep 15) 316-324
21. Jacquet P., Averbach A., Stuart O.A., Chang D., and Sugarbaker P.H. Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism, and tissue distribution in a rat model. Cancer Chemother Pharmacol 41 2 (1998) 147-154
22. ten Bokkel Huinink WW, Heintz APM, Dubbelman R, Franklin H, Mcvie JG. Intraperitoneal carboplatina for refractory ovarian cancer: phase I study. In: Proceedings of the second international conference of intracavitary chemotherapy. San Diego; 1988. p. 47.
23. Ozols R.F., Young R.C., Speyer J.L., et al. Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancers. Cancer Res 42 (1982) 4265-4269
24. Raspagliesi F., Kusamura S., Campos Torres J.C., et al. Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: the experience of National Cancer Institute of Milan. Eur J Surg Oncol 32 6 (2006 Aug) 671-675 [Epub 2006 Apr 18]